CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Understand Which Retirement Index Funds Have Low Fees to spot affordable options. Compare fund families and refine your retirement strategy.
27,548 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
AI stocks have cooled, but durable leaders still offer big upside. This guide highlights three genius artificial inte...
Northeast metros are clearing supply faster than many Sun Belt peers, boosting seller leverage as spring demand retur...
Biotech investors watched Agios Pharmaceuticals spark a notable rally after key quarterly results and a strong Aqvesm...
If you could only artificial intelligence and buy one stock today, Nvidia tops the list for its AI hardware leadershi...
A crypto analyst challenges Ripple’s CEO over Strategy’s BTC funding model as BTC and XRP markets react to evolving f...
Jim Cramer remains wary of Salesforce as growth slows and CIOs shift budgets to less expensive software. He argues th...
Institutional buyers are flocking to STRC, Strategy’s variable-rate perpetual preferred stock, driving an 11% yield a...
Bitcoin hovered near $80,000 as April payrolls undershot forecasts, renewing bets on Fed policy and a potential bitco...
Broadcom posted solid revenue growth and a solid EPS beat, but AI chip guidance disappointed some. This guide breaks ...
Open-source AI is drawing strong backing from investors and consumers alike. Hugging Face cofounder Thomas Wolf argue...
AI-driven models flag XRP as the most likely to post the biggest gains in the second half of 2026, even as Bitcoin an...